ArticleAntimicrobial agents and chemotherapy2019
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- L2 β-lactamase contributes to ceftolozane-tazobactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- Article
- A novel mechanism of ceftolozane-tazobactam resistance inbioRxiv : the preprint server for biology · 2026Article
- Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa.The Journal of infectious diseases · 2026Article
- An improved algorithm to screen for carbapenemase production inJAC-antimicrobial resistance · 2026Article
- Multidrug-resistantVirulence · 2025Review
- Structural comparison of substrate-binding pockets of serine β-lactamases in classes A, C, and D.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Novel resistance ICEs carrying theAntimicrobial agents and chemotherapy · 2024Article
- Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients.Antimicrobial resistance and infection control · 2022Article
- NDM-35-Producing ST167Antimicrobial agents and chemotherapy · 2022Article
- Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics.Signal transduction and targeted therapy · 2022Review
- Combination of phage therapy and cefiderocol to successfully treatJAC-antimicrobial resistance · 2022Article
- Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing Importance.Antimicrobial agents and chemotherapy · 2022Article
- Review
- Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".Infectious disease clinics of North America · 2020Review
- Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of Pseudomonas aeruginosa Isolates.Journal of clinical microbiology · 2020Article
- Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.Antimicrobial agents and chemotherapy · 2020Article
- Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.Antimicrobial agents and chemotherapy · 2019Article
- A 2.5-years within-patient evolution of aAntimicrobial agents and chemotherapy · 2019Article
- Extensively Drug-ResistantOpen forum infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A clinical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.